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Oxaline and neoxaline, fungal alkaloids, were found to inhibit cell proliferation and to induce cell cycle arrest at the G2/M phase in Jurkat
cells. CBP501 (a peptide corresponding to amino acids 211–221 of Cdc25C phosphatase), which inhibits the G2 checkpoint, did not affect
the G2/M arrest caused by oxaline, suggesting that oxaline causes M phase arrest but not G2 phase arrest. The Cdc2 phosphorylation level of
oxaline-treated cell lysate was lower than that of the control cells, indicating that oxaline arrests the M phase. Oxaline disrupted cytoplasmic
microtubule assembly in 3T3 cells. Furthermore, oxaline inhibited polymerization of microtubule protein and purified tubulin dose-
dependently in vitro. In a binding competition assay, oxaline inhibited the binding of [3H]colchicine to tubulin, but not that of
[3H]vinblastine. These results indicate that oxaline inhibits tubulin polymerization, resulting in cell cycle arrest at the M phase.
D 2004 Elsevier B.V. All rights reserved.Keywords: Fungal alkaloid; Oxaline; Cell cycle; Microtubule; Tubulin1. Introduction
Microtubules, which are cytoplasmic fibers with a tubu-
lar form composed of a heterodimer of a- and h-tubulin as
the major component, and microtubule-associated proteins
(MAPs) as the minor ones, are involved in many cellular
functions including mitosis, cell morphogenesis and intra-
cellular transport [1]. There are a number of natural and
synthetic compounds that interfere with microtubule func-
tion to cause arrest of the cell cycle at the M phase. These
compounds are useful biochemical and cytological probes,
and have proven or potential utility as antitumor drugs
[2,3].
Screening for microbial metabolites that have antiproli-
ferative activity and arrest the cell cycle at the G2/M phase
identified oxaline and neoxaline (Fig. 1) as active com-0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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Abbreviations: MAPs, microtubule-associated proteins; HPLC, high
pressure liquid chromatography; MTT, 3-(4,5-dimethylthiazo-2-yl)-2,5-
diphenyl-tetrazolium bromide; SDS, sodium dodecyl sulfate; PBS,
phosphate buffered saline; EGTA, ethylene glycol-bis(h-aminoethyl ether);
PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel electro-
phoresis; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate
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E-mail address: tomoda@lisci.kitasato-u.ac.jp (H. Tomoda).pounds. Oxaline and neoxaline are alkaloids isolated from
the culture broth of Penicillium oxalicum and Aspergillus
japonicus, respectively [4,5]. However, their biological ac-
tivities are largely unknown [5]. These alkaloids possess
several interesting structural features, including an N-OMe
group, an unusual coupling of tryptophan and dehydrohisti-
dine, a single carbon atom having three different nitrogen
substituents and a reversed isoprenyl group [6–8]. The
structure of these alkaloids differs from that of well-known
G2/M arrest inducers such as colchicine, vinblastine and
taxol [2,3]. Thus, in addition to their quite unique chemical
structures, their biological activity prompted us to study the
mechanism of action of these drugs. In this study, we show
that oxaline inhibits microtubule protein/purified tubulin
polymerization, resulting in arrest of the cell cycle at the
M phase.2. Materials and methods
2.1. Chemicals
Oxaline and neoxaline were isolated from a culture of
Penicillium sp. FKI-0779 and A. japonicus Fg-551, respec-
Fig. 1. Structures of oxaline and neoxaline.
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were separated by chromatography on silica gel, and the
alkaloids then purified to >99% by reversed-phase HPLC.
CBP501 [9] was kindly provided by CanBas Co. Ltd (Shi-
zuoka, Japan). Bleomycin was purchased from Nippon
Kayaku (Tokyo, Japan). Colchicine was obtained from Sigma
(St. Louis, MO). [3H]Colchicine was purchased from Perki-
nElmer Life Science (Boston, MA) and [3H]vinblastine from
Amersham Biosciences (Piscataway, NJ). Other reagents
were commercially available analytical grade products.
2.2. Cell culture
Jurkat cells, from a human T cell leukemia, and 3T3 cells,
mouse fibroblasts, were cultured in RPMI-1640 medium and
DMEM, respectively, supplemented with 10% fetal bovine
serum, 100 units/ml penicillin and 100 Ag/ml streptomycin,
in a humidified chamber at 37 jC containing 5% CO2.
2.3. Cell proliferation assay
Cell proliferation was evaluated using the colorimetric 3-
(4,5-dimethylthiazo-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) assay [10]. The exponentially growing cells were
cultured in 96-well plates (Corning Inc., Corning, NY) with
drugs at the indicated concentrations at 37 jC for 48 h. After
incubation, the cells received 10 Al of 5.5 mg/ml MTT in
phosphate buffered saline (PBS), and were then incubated at
37 jC for 4 h. A 90-Al aliquot of extraction solution (40%
(v/v) N,N-dimethylformamide, 2% (v/v) CH3COOH, 20%
(w/v) SDS and 0.03 N HCl) was added, and the mix
incubated at room temperature for 2 h. Cell proliferation
was determined by measuring optical density at 550 nm.
2.4. Flow cytometry
Jurkat cells (1105 cells) were incubated in 96-well
plates with drugs in the presence or absence of CBP501 at
37 jC for various time periods. After removal of condi-
tioned medium, cells were resuspended in 200 Al of 50 Ag/
ml propidium iodide, 20 Ag/ml RNase A, 0.1% (w/v)
sodium citrate and 0.3% (w/v) Nonident P-40, and incubat-
ed at room temperature for 2 h. DNA content was deter-
mined using FACSCalibur analysis (Becton Dickinson,Franklin Lakes, NJ). Data analysis was performed using
ModFit LT software for cell cycle profiles.
2.5. Immunoprecipitation and immunoblotting
Jurkat cells (4 106 cells) were incubated in the presence
or absence of the drugs for 20 h. After incubation, cells were
washed twice with PBS and lysed in 500 Al of lysis buffer
(50 mM Tris–HCl (pH 7.4) and 150 mM NaCl containing
1% (w/v) Nonident P-40, 0.25% (w/v) sodium deoxycho-
late, 0.1% (w/v) SDS, 1 mM EGTA, 1 mM PMSF, 1 Ag/ml
aprotinin, 1 Ag/ml leupeptin, 1 Ag/ml pepstatin A, 1 mM
Na3VO4 and 1 mM NaF) at 4 jC for 30 min. Cell lysates
were clarified by centrifugation, and the resultant super-
natants used for protein quantitation using the BCA protein
assay reagents (Pierce, Rockford, IL). Fifty micrograms of
each cell lysate was reacted with 2 Ag/ml of anti-Cdc2
antibody (A17.1.1, Oncogene, Boston, MA) in 250 Al of 5%
(v/v) Protein A-Sepharose slurry (Amersham Biosciences)
in lysis buffer of one third strength at 4 jC overnight.
Immunoprecipitates were then washed extensively with one
third strength lysis buffer, eluted by boiling for 3 min in 25
Al of SDS sample buffer and separated by 12.5% SDS-
PAGE. After electrophoresis, the proteins were transferred
to Immobilon-P membrane (Millipore, Bedford, MA).
Membranes were blocked in 20 mM Tris–HCl (pH 7.4),
100 mM NaCl and 0.1% (w/v) Tween 20 (TBS/T) contain-
ing 5% BSA for 1 h and then probed with 1 Ag/ml of anti-
Cdc2 antibody or anti-phosphotyrosine antibody (4G10,
Upstate Biotechnology, Lake Placid, NY) for 1 h. After
washing, the membranes were incubated with 0.2 Ag/ml of
peroxidase-conjugated anti-mouse antibody (Sigma) for 1 h.
Membranes were then washed, and proteins subsequently
detected using an enhanced chemiluminescence (ECL) sys-
tem (Amersham Biosciences).
2.6. Immunofluorescence
3T3 cells were cultured on eight-chamber slides for 20 h,
and then incubated for 5 h in the presence or absence of the
drugs. After removal of the medium, cells were fixed in
3.7% paraformaldehyde for 30 min. After washing, cells
were permeabilized with 0.1% Triton X-100 and 4 Ag/ml
RNase A in PBS for 1 h. Cells were then washed, and
incubated with 36 Ag/ml of FITC-conjugated anti-a-tubulin
antibody (Sigma) and 1 Ag/ml propidium iodide in PBS for
1 h in the dark. The cells were washed and mounted with
aqueous mounting medium. Microtubules and DNA were
observed using a Confocal Laser Scanning Microscope TCS
NT (Leica Microsystems AG, Wetzlar, Germany).
2.7. Microtubule protein and purified tubulin polymeriza-
tion assay
Polymerization assays for microtubule protein and puri-
fied tubulin were performed using the CytoDYNAMIX
Fig. 2. Antiproliferative activity of oxaline and neoxaline. Jurkat cells were
incubated in 96-well plates with oxaline (.), neoxaline (E) or colchicine
(o) at the indicated concentrations for 48 h. After treatment, cell viability
was evaluated by MTT assay. Each value represents the meanF S.D. from
triplicate determinations.
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manufacturer’s instructions. Briefly, microtubule protein (2
mg/ml) or purified tubulin (3 mg/ml) was incubated at 37
jC in the presence or absence of the drugs, and polymer-
ization then detected by measuring the change in absorbance
at 340 nm.
2.8. Tubulin purification
Microtubule protein was prepared from porcine brain
using the polymerization-depolymerization method of She-
lanski et al. [11] with a slight modification. Microtubule
protein, which was purified by two cycles of polymeriza-
tion-depolymerization, was dissolved in MES buffer (20
mM MES (pH 6.8), 0.5 mM MgCl2, 1 mM EGTA and 0.1
mM GTP). Tubulin was purified from microtubule protein
by phosphocellulose (P11, Whatman, Kent, UK) column
chromatography [12].
2.9. Competition assay
A competition assay was performed using the centrifugal
gel filtration method [13] with minor modifications. A 100-
Al aliquot of 0.5 mg/ml tubulin purified from porcine brain
was incubated with 100 nM [3H]colchicine or [3H]vinblas-
tine in the presence or absence of the indicated concentra-
tion of drugs for 10 min at room temperature. After
incubation, the mixture was loaded onto a 1-ml spin column
filled with Sephadex G-50 (Superfine, Amersham Bioscien-
ces), and centrifuged at 1500 rpm for 5 min to obtain the
tubulin fraction. The radioactivity of [3H]ligand bound to
tubulin was measured using the Wallac Micro Beta Trilax
(PerkinElmer Life Science) system.3. Results
3.1. Oxaline and neoxaline have antiproliferative activity
and arrest the cell cycle at the G2/M phase
The antiproliferative activity of oxaline and neoxaline
against human T cell leukemia Jurkat cells was evaluated by
MTT assay after 48-h treatment. Both alkaloids inhibited
cell proliferation in a dose-dependent manner. The IC50
values of oxaline and neoxaline were 8.7 and 43.7 AM,
respectively, while that of colchicine was 6.8 nM (Fig. 2).
The effect of these alkaloids on the cell cycle of Jurkat
cells was examined using a flow cytometer. Jurkat cells
were treated with various concentrations of alkaloids for 20
h, and stained with propidium iodide for cell cycle analysis.
Accumulation at the G2/M phase was observed by treatment
with 20 AM oxaline or 70 AM neoxaline, and the maximum
effects of oxaline and neoxaline were observed at 70 and
200 AM, respectively (Fig. 3A). The G2/M arrest by these
alkaloids increased time-dependently from treatment times
of 0 to 15–20 h, followed by a decrease in the number ofG2/M arrest cells and an increase in sub G1 cells, indicative
of apoptotic cells (Fig. 3B). In contrast, the cell cycle status
of control cells remained fundamentally unchanged for 0 to
40 h (Fig. 3B). In these cell assays, oxaline was several
times more potent than neoxaline; so further studies were
performed using oxaline.
3.2. Oxaline arrests the cell cycle reversibly
We tested whether the G2/M arrest by oxaline was
reversible. As shown in Fig. 3B, the oxaline effect was
visible after 5 h of treatment. Therefore, Jurkat cells were
pretreated with oxaline for 8 h, washed and then incubated
with or without oxaline for 12 h. The proportion of G2/M
phase of oxaline-treated cells was 43.8%, whereas that of
oxaline-pretreated cells was 4.0% (Table 1). Although oxa-
line-pretreated cells underwent apoptosis slightly, most cells
recovered from G2/M arrest to G1/S phase by removal of
oxaline, indicating that the effect of oxaline is reversible.
3.3. CBP501 does not affect the G2/M arrest caused by
oxaline
Although oxaline arrests the cell cycle at the G2/M phase,
it is unclear whether this arrest occurs in the G2 or M phase.
Thus, we used CBP501, a peptide corresponding to amino
acids 211–221 of Cdc25C phosphatase, which is an inhib-
itor of G2 checkpoint [9]. DNA damage activates a cell
cycle checkpoint that prevents the progression to M phase
while DNA repair is under way [14]. In the G2 checkpoint,
Cdc25C, which activates Cdc2 involved in G2/M transition,
is phosphorylated at Ser216 by Chk1 or Chk2 and is
exported from nucleus to cytoplasm through the binding
Fig. 3. Effects of oxaline and neoxaline on cell cycle progression. Jurkat cells were incubated in 96-well plates with oxaline or neoxaline at the indicated
concentrations for 20 h (A), or with 70 AM oxaline or 140 AM neoxaline for the indicated time periods (B). After treatment, cells were stained with propidium
iodide, and cell cycle analysis performed using a flow cytometer. The percentages of cells arrested in G2/M phase were listed on each histogram.
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phosphorylation form [15–21]. CBP501 inhibits the DNA
damage-dependent phosphorylation of Cdc25C by Chk1
and Chk2 and induces cell death [9]. As shown in Fig. 4,
although bleomycin, a potent DNA-damage inducer, and
colchicine, a microtubule polymerization inhibitor, arrest the
cell cycle at the G2 phase and M phase, respectively, the
histograms of the two drugs show similar cell cycle distri-
bution in G2/M arrest. In combination with CBP501, G2
arrest induced by bleomycin was abrogated, and sub G1
cells increased. In contrast, colchicine-treated cells showed
no change (Fig. 4). Oxaline-treated cells also showed no
change in combination with CBP501, suggesting that oxa-
line induces arrest of the cell cycle at the M phase, but not
G2 phase.3.4. Tyrosine of Cdc2 prepared from oxaline-treated cells
are dephosphorylated
The progression from G2 to M phase requires activation
of the Cdc2 and cyclin B complex. The activation of Cdc2/
cyclin B is regulated by dephosphorylation of Cdc2 at Thr14
and Tyr15 catalyzed by Cdc25C [21–26]. Therefore, since
the inhibitory phosphorylation of Cdc2 at G2 phase is
dephosphorylated with the progression to M phase, the
Cdc2 phosphorylation level becomes the index that shows
that the cell cycle status is in either G2 or M phase. To
determine the phosphorylation level of Cdc2, we used
immunoprecipitation and immunoblotting techniques.
Drug-treated or untreated cell lysates were immunoprecipi-
tated using anti-Cdc2 antibody, followed by detection by
Fig. 5. Effect of oxaline on the phosphorylation of Cdc2. Jurkat cells were
incubated with or without 40 AM bleomycin, 0.5 AM colchicine, or 10 or 70
AM oxaline for 20 h. After incubation, cells were lysed and immunopre-
cipitated with anti-Cdc2 antibody. Immunoprecipitates were separated on
12.5% SDS-PAGE followed by immunoblotting with anti-Cdc2 antibody or
anti-phosphotyrosine antibody. Proteins were detected using the ECL
system.
Table 1
Cell cycle profile of cells treated or pretreated with oxaline
Cell count (%)
Sub G1 G1 S G2/M
Control cells 2.2 45.7 32.0 13.9
Oxaline-treated cells 35.0 0.8 11.4 43.8
Oxaline-pretreated cells 15.3 34.9 39.7 4.0
Jurkat cells were pretreated with oxaline (70 AM) for 8 h, washed and then
incubated with or without oxaline (70 AM) for 12 h. After incubation, cells
were stained with propidium iodide, and DNA content was determined
using a flow cytometer. Data analysis was performed by ModFit LT for cell
cycle profiles.
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tibody (Fig. 5). Cdc2 levels in each lysate were almost
identical. However, bleomycin increased the phosphotyro-
sine level of Cdc2, indicating that bleomycin arrested the cell
cycle in the G2 phase. In contrast, oxaline, as well as
colchicine, induced the dephosphorylation of Cdc2, and
the phosphotyrosine levels were lower than those of the
control cells. Thus, Jurkat cells treated with oxaline arrest in
the M phase.
3.5. Oxaline disrupts cytoplasmic microtubule assembly in
3T3 cells
These results indicate that the effects of oxaline on
Jurkat cells resemble those of colchicine. Colchicine inhib-
its the polymerization of microtubules, resulting in arrest
of the cell cycle at the M phase. We examined the effect of
oxaline on cytoplasmic microtubules in mouse fibroblast
3T3 cells by immunofluorescence staining with FITC-Fig. 4. Effect of G2 checkpoint inhibitor on cell cycle progression of oxaline-treate
bleomycin, 0.5 AM colchicine or 70 AM oxaline in the presence or absence of 30
iodide, and cell cycle analysis performed using a flow cytometer.conjugated anti-a-tubulin antibody. The microtubule as-
sembly of control cells was clearly visible (Fig. 6A),
whereas oxaline completely disrupted microtubule assem-
bly, as did colchicine (Fig. 6B and C). Oxaline did not
affect actin filaments, which are different cytoskeletal
proteins, in 3T3 cells (data not shown).
3.6. Oxaline inhibits polymerization of microtubule protein
and purified tubulin in vitro
Next, we investigated whether oxaline affects microtu-
bule polymerization in vitro. After treatment of unpoly-d cells. Jurkat cells were incubated in 96-well plates with or without 40 AM
Ag/ml CBP501 for 20 h. After treatment, cells were stained with propidium
Fig. 6. Effect of oxaline on microtubule assembly in 3T3 cells. 3T3 cells
were cultured on eight-chamber slides for 20 h, and then incubated for 5
h without (A), or with 0.5 AM colchicine (B) or 70 AM oxaline (C). After
removal of the medium, cells were fixed and permeated. Cells were then
incubated with FITC-conjugated anti-a-tubulin antibody and propidium
iodide. Microtubules (green) and DNA (red) were observed using a
Confocal Laser Scanning Microscope. Bar, 50 Am.
Fig. 7. Effects of oxaline on microtubule protein and purified tubulin
polymerization. Polymerization assays for microtubule protein (A) and
purified tubulin (B) were performed using commercial kits. Microtubule
proteins (2 mg/ml) or purified tubulin (3 mg/ml) was incubated at 37 jC
with 2% (v/v) DMSO. Polymerization was detected by measuring the
change in absorbance at 340 nm. Final concentrations of oxaline and
colchicine were 0 (o), 10 (.), 20 (x), 70 (n) or 130 AM (E) and 10 AM
(w), respectively. The values of IC50 of colchicine were 2–5 AM in these
assay (data not shown).
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340 nm that indicated polymerization levels were mea-
sured at 37 jC (Fig. 7A). Oxaline inhibited polymerization
of microtubules dose-dependently. The microtubule pro-teins used here contained approximately 90% tubulin and
10% MAPs. Colchicine is known to inhibit tubulin poly-
merization specifically to block microtubule polymeriza-
tion. On the other hand, some compounds (griseofluvin,
estramustine phosphate, tryprostatin A) inhibit microtubule
polymerization as a result of interfering with the interac-
tion between tubulin and MAPs [27–31]. To test whether
oxaline affects tubulin directly or the interaction with
tubulin-MAPs, we examined the effect of oxaline on
purified tubulin polymerization. As shown in Fig. 7B,
oxaline, as well as colchicine, inhibited tubulin polymer-
ization. The IC50 value of oxaline was 107 AM. Thus, we
Fig. 8. Effect of oxaline on binding of [3H]colchicine and [3H]vinblastine to purified tubulin. One-hundred-microliter aliquot of 0.5 mg/ml purified tubulin was
incubated with 100 nM [3H]colchicine (A) or [3H]vinblastine (B) in the absence ( ) or presence of colchicine (100 AM, ), vinblastine (100 AM, ) or oxaline
(100 AM, ; 300 AM, ; 1 mM, ) for 10 min at room temperature. After incubation, the mixture was applied to a 1-ml column of Sephadex G-50, and
centrifuged at 1500 rpm for 5 min to obtain the tubulin fraction. The radioactivity of [3H]ligand bound to tubulin was measured using the Wallac Micro Beta
Trilax system. Each value represents the meanF S.D. from triplicate determinations.
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through inhibition of tubulin polymerization.
3.7. Oxaline inhibits the binding of [3H]colchicine to
tubulin
Studies on the binding sites of tubulin polymerization
inhibitors have revealed that colchicine and vinblastine have
different sites of action on tubulin [3]. To determine the
binding site of oxaline on tubulin, we further examined the
effect of oxaline on binding of [3H]colchicine and [3H]vin-
blastine to purified tubulin (Fig. 8). Unlabelled colchicine
and vinblastine decreased the binding of [3H]colchicine and
[3H]vinblastine, respectively. Oxaline weakly inhibited
[3H]colchicine binding to tubulin at 10,000-fold concentra-
tion (30% inhibition), while no effect of oxaline was ob-
served on binding of [3H]vinblastine even at the highest
concentration.4. Discussion
Although a large number of bioactive compounds with
a variety of chemical structures have been discovered from
natural resources such as microorganism and plants, their
target molecules or functions in cells or living organisms
have not been well defined in most cases. Oxaline and
neoxaline were originally isolated as fungal alkaloids with
a highly unique structure, as shown in Fig. 1 [4–8].
Meleagrin and glandicolins are known analogs, with an
unusual coupling of tryptophan and dehydrohistidine, a
single carbon atom having three different nitrogen sub-
stituents and a reversed isoprenyl group, as seen in oxaline
and neoxaline [32–34]. However, the biological activitiesof oxaline and neoxaline have not been fully determined
[5]. In the present study, we found first that these alkaloids
inhibit cell proliferation and arrest the cell cycle at the G2/
M phase in Jurkat cells. The result of both the effect of a
G2 checkpoint abrogator and the decrease in Cdc2 phos-
phorylation level showed that oxaline arrests the cell cycle
in the M phase but not in the G2 phase. There are a
number of natural and synthetic compounds that cause cell
cycle arrest at the M phase. In particular, colchicine,
vinblastine and taxol have been extensively investigated
for their practical uses, as well as for use as biochemical
and cytological probes. These compounds are well known
to inhibit microtubule functions [2,3,35]. Oxaline also
disrupted cytoplasmic microtubule assembly and inhibited
the polymerization of microtubule proteins and purified
tubulin as well as the above compounds. The result of the
binding competition assay using [3H]colchicine or [3H]vin-
blastine is unclear, as oxaline inhibited [3H]colchicine
binding to tubulin by only approximately 30% at 10,000-
fold higher concentration. It may be that oxaline binds near
the colchicine binding site in tubulin or that the interaction
between oxaline and tubulin is unstable compared to
colchicines, even if oxaline has the same binding site as
colchicine.
Oxaline is biosynthesized by fungal strains from the
precursor diketopiperazine composed of tryptophan and the
dehydrohistidine, roquefortine [36–38]. Recently, two
diketopiperazines, tryprostatin A and ( )-phenylahistine,
have been reported as inhibitors of microtubule protein
polymerization [30,31,39]. The former is composed of
tryptophan and proline, and the latter of phenylalanine
and dehydrohistidine. Although these compounds have a
similar structural motif, the mechanisms of action are
different. Tryprostatin A inhibits the interaction between
Y. Koizumi et al. / Biochimica et Biophysica Acta 1693 (2004) 47–5554tubulin and MAP2/tau, and ( )-phenylahistine binds to
tubulin at the colchicine binding site. However, roquefor-
tine has no effect on the cell cycle distribution in Jurkat
cells even at 250 AM (data not shown). These observations
bring us the interest to the investigation on the structure–
activity relationship of diketopiperazines.
This is the first demonstration of the mechanism of action
of fungal oxaline, which has a unique structure. Further
study of the structure–activity relationship among oxaline
analogs might lead to the development of a new type of
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